Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Xbrane Biopharma AB's EBITDA for the
three
months ended in Jun. 2026 was kr-9.00 Mil. Xbrane Biopharma AB's Revenue for the
three
months ended in Jun. 2026 was kr46.75 Mil. Therefore, Xbrane Biopharma AB's EBITDA margin for the quarter that ended in Jun. 2026 was -19.25%.
Xbrane Biopharma AB (OSTO:XBRANE) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Xbrane Biopharma AB EBITDA Margin % Related Terms
Xbrane Biopharma AB EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Xbrane Biopharma AB's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:XBRANE vs VRTX, REGN, RVMD: EBITDA Margin % Comparison
For the Biotechnology subindustry, Xbrane Biopharma AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xbrane Biopharma AB EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xbrane Biopharma AB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Xbrane Biopharma AB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xbrane Biopharma AB (OSTO:XBRANE) has a EBITDA Margin % of -19.25% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Xbrane Biopharma AB and its competitors. According to the industry distribution chart, Xbrane Biopharma AB ranks #497 out of 940 companies in the Biotechnology industry, placing it in the top 52.9%.
Is Xbrane Biopharma AB's EBITDA Margin % too high?
Xbrane Biopharma AB's current EBITDA Margin % is -19.25%. Based on the distribution chart, Xbrane Biopharma AB ranks #497 out of 940 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Xbrane Biopharma AB has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xbrane Biopharma AB's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Xbrane Biopharma AB ranks #497 out of 940 companies for EBITDA Margin %. This places Xbrane Biopharma AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Xbrane Biopharma AB and its competitors. Xbrane Biopharma AB's current EBITDA Margin % is -19.25%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xbrane Biopharma AB stock overvalued right now?
Based on GuruFocus' analysis, Xbrane Biopharma AB (OSTO:XBRANE) is currently considered Significantly Overvalued. The stock's GF Value™ is kr5.97, compared to a current price of kr9.18 — trading 53.8% above its estimated fair value. The current EBITDA Margin % is -19.25%. Xbrane Biopharma AB's overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Xbrane Biopharma AB (OSTO:XBRANE), the current EBITDA Margin % is -19.25% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xbrane Biopharma AB (OSTO:XBRANE) Overvalued in 2026?
Based on GuruFocus' analysis, Xbrane Biopharma AB stock appears to be overvalued.
The current stock price of kr9.18 is trading 53.8% above its estimated GF Value™ of kr5.97.
GuruFocus considers Xbrane Biopharma AB to be Significantly Overvalued.
Key valuation signals for OSTO:XBRANE:
EBITDA Margin %: -19.25%
GF Value™: kr5.97 vs. price of kr9.18 (53.8% above fair value)
No single metric tells the full story. See the OSTO:XBRANE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company follows drugs on already approved biological drugs that can be introduced at a lower price after the patent expires on the original drug. The company has a patented protein production platform with greater productivity than standard systems for producing proteins in E.coli host cells. The company's product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration. Other products in preclinical stage of the company includes Xdivane and Xdarzane.
71GF Score
Get the complete analysis for OSTO:XBRANE
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:XBRANE has been successfully added to your 
